LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test for Early-Onset Alzheimer's Disease Relies on Exosomal MicroRNA Biomarkers

By LabMedica International staff writers
Posted on 09 Nov 2014
Print article
A team of Australian biomedical researchers has devised a blood test based on expression profiling of small non-coding RNA’s, microRNA (miRNA), for the diagnosis of early-onset Alzheimer's disease (AD).

Investigators at the University of Melbourne (Australia) identified a set of differential exosomal miRNA biomarkers that differentiate between healthy individuals and AD patients. They adapted a panel of these miRNAs—snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA—obtained from small serum vesicles known as exosomes for screening of potential AD sufferers.

For this purposed they used a next-generation deep sequencing technique to profile exosomal miRNA from serum collected from 49 participants in the Australian Imaging, Biomarkers, and Lifestyle Flagship Study (AIBL). Sequencing results were validated using quantitative reverse transcription PCR (qRT-PCR). Additional risk factors collected during the 4.5-year AIBL Study including clinical, medical, and cognitive assessments, and amyloid neuroimaging with positron emission tomography were assessed.

An AD-specific 16-miRNA signature was selected, and adding established risk factors including age, sex, and apolipoprotein epsilon-4 (APOE epsilon-4) allele status to the miRNA panel resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD.

First author Dr. Lesley Cheng, a post-doctoral researcher in biochemistry, molecular and cell biology at the University of Melbourne, said, “This test provides the possibility of early detection of AD by using a simple blood test which has been designed to also be cost-effective. Furthermore, it is highly accessible for patients and physicians compared to organizing a brain scan or undergoing a neuropsychological test. Patients with a family history of AD or those with memory concerns could be tested during a standard health check at a medical clinic. This test could ease concerns for patients experiencing normal memory problems due to natural ageing. Those identified as high risk could then be monitored by their doctor."

The miRNA biomarker study was published in the October 28, 2014, online edition of the journal Molecular Psychiatry.

Related Links:

University of Melbourne


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more